Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 723

1.

Validation of the 12-gene predictive signature for Adjuvant Chemotherapy Response in Lung Cancer.

Xie Y, Lu W, Wang S, Tang X, Tang H, Zhou Y, Moran C, Behrens C, Roth JA, Zhou Q, Johnson DH, Swisher SG, Heymach JV, Papadimitrakopoulou VA, Xiao G, Minna JD, Wistuba II.

Clin Cancer Res. 2018 Oct 4. pii: clincanres.2543.2017. doi: 10.1158/1078-0432.CCR-17-2543. [Epub ahead of print]

PMID:
30287547
2.

Different Originating Cells Underlie Intertumoral Heterogeneity in Lung Neuroendocrine Tumors.

Pozo K, Kelenis DP, Minna JD, Johnson JE.

Cancer Discov. 2018 Oct;8(10):1216-1218. doi: 10.1158/2159-8290.CD-18-0979.

PMID:
30279195
3.

A quantitative method for assessing smoke associated molecular damage in lung cancers.

Song K, Bi JH, Qiu ZW, Felizardo R, Girard L, Minna JD, Gazdar AF.

Transl Lung Cancer Res. 2018 Aug;7(4):439-449. doi: 10.21037/tlcr.2018.07.01.

4.

Estrogen Receptor Beta-Mediated Modulation of Lung Cancer Cell Proliferation by 27-Hydroxycholesterol.

Hiramitsu S, Ishikawa T, Lee WR, Khan T, Crumbley C, Khwaja N, Zamanian F, Asghari A, Sen M, Zhang Y, Hawse JR, Minna JD, Umetani M.

Front Endocrinol (Lausanne). 2018 Aug 23;9:470. doi: 10.3389/fendo.2018.00470. eCollection 2018.

5.

HORMAD1 is a negative prognostic indicator in lung adenocarcinoma and specifies resistance to oxidative and genotoxic stress.

Nichols BA, Oswald NW, McMillan EA, McGlynn K, Yan J, Kim MS, Saha J, Mallipeddi PL, LaDuke SA, Villalobos PA, Rodriguez-Canales J, Wistuba II, Posner BA, Davis AJ, Minna JD, MacMillan JB, Whitehurst AW.

Cancer Res. 2018 Sep 5. pii: canres.1377.2018. doi: 10.1158/0008-5472.CAN-18-1377. [Epub ahead of print]

PMID:
30185546
6.

Corrigendum: Identifying a missing lineage driver in a subset of lung neuroendocrine tumors.

Pozo K, Minna JD, Johnson JE.

Genes Dev. 2018 Sep 1;32(17-18):1266. doi: 10.1101/gad.319129.118. No abstract available.

7.

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.

Motea EA, Fattah FJ, Xiao L, Girard L, Rommel A, Morales JC, Patidar P, Zhou Y, Porter A, Xie Y, Minna JD, Boothman DA.

Clin Cancer Res. 2018 Aug 14. doi: 10.1158/1078-0432.CCR-17-1118. [Epub ahead of print]

PMID:
30108102
8.

Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers.

Huang F, Ni M, Chalishazar MD, Huffman KE, Kim J, Cai L, Shi X, Cai F, Zacharias LG, Ireland AS, Li K, Gu W, Kaushik AK, Liu X, Gazdar AF, Oliver TG, Minna JD, Hu Z, DeBerardinis RJ.

Cell Metab. 2018 Sep 4;28(3):369-382.e5. doi: 10.1016/j.cmet.2018.06.005. Epub 2018 Jun 28.

PMID:
30043754
9.

LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.

Du L, Zhao Z, Suraokar M, Shelton SS, Ma X, Hsiao TH, Minna JD, Wistuba I, Pertsemlidis A.

Oncotarget. 2018 Jul 3;9(51):29601-29618. doi: 10.18632/oncotarget.25642. eCollection 2018 Jul 3.

10.

Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.

Mender I, LaRanger R, Luitel K, Peyton M, Girard L, Lai TP, Batten K, Cornelius C, Dalvi MP, Ramirez M, Du W, Wu LF, Altschuler SJ, Brekken R, Martinez ED, Minna JD, Wright WE, Shay JW.

Neoplasia. 2018 Aug;20(8):826-837. doi: 10.1016/j.neo.2018.06.002. Epub 2018 Jul 6.

11.

Retraction notice to "Sun exposure related methylation in malignant and non-malignant skin lesions" [Cancer Letters 245/1-2 (2007) 112-120].

Sathyanarayana UG, Moore AY, Li L, Padar A, Majmudar K, Stastny V, Makarla P, Suzuki M, Minna JD, Feng Z, Gazdar AF.

Cancer Lett. 2018 Sep 28;432:272. doi: 10.1016/j.canlet.2018.07.010. No abstract available.

PMID:
30007586
12.

Identifying a missing lineage driver in a subset of lung neuroendocrine tumors.

Pozo K, Minna JD, Johnson JE.

Genes Dev. 2018 Jul 1;32(13-14):865-867. doi: 10.1101/gad.316943.118. Erratum in: Genes Dev. 2018 Sep 1;32(17-18):1266.

PMID:
29967289
13.

Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.

Rashdan S, Minna JD, Gerber DE.

Lancet Respir Med. 2018 Jun;6(6):472-478. doi: 10.1016/S2213-2600(18)30172-3.

PMID:
29856320
14.

Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer.

McMillan EA, Ryu MJ, Diep CH, Mendiratta S, Clemenceau JR, Vaden RM, Kim JH, Motoyaji T, Covington KR, Peyton M, Huffman K, Wu X, Girard L, Sung Y, Chen PH, Mallipeddi PL, Lee JY, Hanson J, Voruganti S, Yu Y, Park S, Sudderth J, DeSevo C, Muzny DM, Doddapaneni H, Gazdar A, Gibbs RA, Hwang TH, Heymach JV, Wistuba I, Coombes KR, Williams NS, Wheeler DA, MacMillan JB, Deberardinis RJ, Roth MG, Posner BA, Minna JD, Kim HS, White MA.

Cell. 2018 May 3;173(4):864-878.e29. doi: 10.1016/j.cell.2018.03.028. Epub 2018 Apr 19.

PMID:
29681454
15.

Evaluating tumor-suppressor gene combinations.

Kim J, Minna JD.

Nat Genet. 2018 Apr;50(4):480-482. doi: 10.1038/s41588-018-0095-y. No abstract available.

PMID:
29632378
16.

eIF2╬▓, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer.

Tanaka I, Sato M, Kato T, Goto D, Kakumu T, Miyazawa A, Yogo N, Hase T, Morise M, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y.

Cancer Sci. 2018 Jun;109(6):1843-1852. doi: 10.1111/cas.13602. Epub 2018 May 25.

17.

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.

Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA.

J Clin Invest. 2018 Jun 1;128(6):2500-2518. doi: 10.1172/JCI96148. Epub 2018 May 7.

18.

Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.

Zhang W, Girard L, Zhang YA, Haruki T, Papari-Zareei M, Stastny V, Ghayee HK, Pacak K, Oliver TG, Minna JD, Gazdar AF.

Transl Lung Cancer Res. 2018 Feb;7(1):32-49. doi: 10.21037/tlcr.2018.02.02.

19.

Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells.

Walser TC, Jing Z, Tran LM, Lin YQ, Yakobian N, Wang G, Krysan K, Zhu LX, Sharma S, Lee MH, Belperio JA, Ooi AT, Gomperts BN, Shay JW, Larsen JE, Minna JD, Hong LS, Fishbein MC, Dubinett SM.

Cancer Res. 2018 Apr 15;78(8):1986-1999. doi: 10.1158/0008-5472.CAN-17-0315. Epub 2018 Feb 5.

PMID:
29431637
20.

The Epithelial Sodium Channel (╬▒ENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors.

He M, Liu S, Gallolu Kankanamalage S, Borromeo MD, Girard L, Gazdar AF, Minna JD, Johnson JE, Cobb MH.

Transl Oncol. 2018 Apr;11(2):292-299. doi: 10.1016/j.tranon.2018.01.004. Epub 2018 Feb 2.

Supplemental Content

Loading ...
Support Center